Tsuyoshi Ishikawa

Tsuyoshi Ishikawa

Auto-generated profile, based on publicly available information

Tsuyoshi Ishikawa

Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine Ube Yamaguchi Japan

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2020 in Hepatology Communications
Verified
Journal Article
Open access
PDF file
YKYurika Kotoh
Yurika Kotoh
YSYutaka Suehiro
Yutaka Suehiro
ISIssei Saeki
Issei Saeki
THTomomi Hoshida
Tomomi Hoshida
MMMasaki Maeda
Masaki Maeda
Takahiro YamasakiTakahiro Yamasaki
Takahiro Yamasaki
Liquid biopsies are not used in practice for hepatocellular carcinoma (HCC). Epi proColon is the first commercial blood‐based test for colorectal cancer screening based on methylated DNA testing of the septin 9 gene (SEPT9). However, Epi proColon has some disadvantages, including the requirement of a large amount of blood and lack of quantitative performance. Therefore, we previously developed a novel liquid biopsy test that can quantitatively detect even a single copy of methylated SEPT9 in a small amount of DNA. In the current study, we evaluated the application potential of this assay for diagnosing HCC. Study subjects included 80 healthy volunteers, 45 patients with chronic liver disease (CLD) without HCC, and 136 patients with HCC (stage 0, 12; stage A, 50; stage B, 31; stage C, 41; and stage D, 2), according to the Barcelona Clinic Liver Cancer staging system. For the assay, DNA was treated with methylation‐sensitive restriction enzymes in two steps, followed by multiplex droplet digital polymerase chain reaction. The median copy number of methylated SEPT9 was 0.0, 2.0, and 6.4 in the healthy control, CLD, and HCC groups, respectively, with significant differences among the groups (HCC vs. healthy control, P < 0.001; HCC vs. CLD, P = 0.002; CLD vs. healthy control, P = 0.008). Assay sensitivity and specificity were 63.2% and 90.0%, respectively (cutoff value, 4.6 copies), in detecting HCC when compared with healthy subjects. The positive rate of methylated SEPT9 increased with HCC progression (stage 0, 41.7%; stage A, 58.0%; stage B, 61.3%; stage C, 75.6%; and stage D, 100%). Conclusion: We developed a sensitive methylated SEPT9 assay that might serve as a liquid biopsy test for diagnosing HCC.

25 March 2020 in Cancers
Verified
Journal Article
Open access
PDF file
ISIssei Saeki
Issei Saeki
Takahiro YamasakiTakahiro Yamasaki
Takahiro Yamasaki
SYSatoyoshi Yamashita
Satoyoshi Yamashita
THTadasuke Hanazono
Tadasuke Hanazono
YUYohei Urata
Yohei Urata
ISIsao Sakaida
Isao Sakaida
There are limited reports regarding early predictors of objective response (OR) in patients with hepatocellular carcinoma (HCC) treated with lenvatinib. This retrospective study including 70 patients aimed to investigate the efficacy of hepatic biochemical markers. Changes in tumor marker (alpha-fetoprotein (AFP)/des-gamma-carboxy prothrombin (DCP)) levels and albumin–bilirubin (ALBI) score between the baseline value and that estimated one month after treatment were evaluated. We identified several predictors of OR, including changes in tumor marker levels. The OR rate calculated using modified Response Evaluation Criteria in Solid Tumor (mRECIST) was 41.4%. Response was defined as a reduction in AFP and DCP levels of ≥40% from baseline. OR was significantly associated with AFP response, but not with DCP. Predictors of OR were evaluated in two groups (high-AFP group: baseline AFP ≥ 10 ng/mL; low-AFP group: remaining patients). A multivariate analysis identified AFP response (odds ratio, 51.389; p = 0.001) and ALBI score (odds ratio, 6.866; p = 0.039) as independent predictors of OR in the high-AFP and low-AFP groups, respectively. Changes in the ALBI score indicated deterioration in both responders and non-responders, with a significant difference in non-responders (p = 0.003). AFP response, baseline ALBI score, and change in the ALBI score were early predictors of OR in patients with HCC undergoing lenvatinib treatment.

5 October 2013 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
TITsuyoshi Ishikawa
Tsuyoshi Ishikawa
SSShogo Shiratsuki
Shogo Shiratsuki
TMTakashi Matsuda
Takashi Matsuda
TITakuya Iwamoto
Takuya Iwamoto
TTTaro Takami
Taro Takami
ISIsao Sakaida
Isao Sakaida

10 March 2005 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
TYTakahiro Yamasaki
Takahiro Yamasaki
TKTeruaki Kimura
Teruaki Kimura
FKFumie Kurokawa
Fumie Kurokawa
KAKouji Aoyama
Kouji Aoyama
TITsuyoshi Ishikawa
Tsuyoshi Ishikawa
KOKiwamu Okita
Kiwamu Okita

7 June 2018 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
TITsuyoshi Ishikawa
Tsuyoshi Ishikawa
RSRyo Sasaki
Ryo Sasaki
TNTatsuro Nishimura
Tatsuro Nishimura
TMTakashi Matsuda
Takashi Matsuda
MMMasaki Maeda
Masaki Maeda
ISIsao Sakaida
Isao Sakaida

2 August 2018 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
TITsuyoshi Ishikawa
Tsuyoshi Ishikawa
RSRyo Sasaki
Ryo Sasaki
TNTatsuro Nishimura
Tatsuro Nishimura
TMTakashi Matsuda
Takashi Matsuda
MMMasaki Maeda
Masaki Maeda
ISIsao Sakaida
Isao Sakaida